Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 15/20 | 0.56 |
| ▸ | PDE4A | P27815 | 3/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.46 |
| ▸ | PDE6D | O43924 | 1/20 | 0.43 |
| ▸ | PDE6A | P16499 | 1/20 | 0.43 |
| ▸ | PDE6G | P18545 | 1/20 | 0.43 |
| ▸ | PDE6B | P35913 | 1/20 | 0.43 |
| ▸ | PDE6C | P51160 | 1/20 | 0.43 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.43 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7545376 | 1.00 | PDE5A (0.56) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL232826 | 0.91 | PDE5A (0.59) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL194126 | 0.91 | PDE5A (0.59) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL194125 | 0.91 | PDE5A (0.59) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL716866 | 0.84 | PDE5A (0.59) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7438566 | 0.84 | PDE5A (0.59) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL194179 | 0.84 | PDE5A (0.64) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL714019 | 0.84 | PDE5A (0.62) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL715367 | 0.82 | PDE5A (0.61) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL194127 | 0.82 | PDE5A (0.61) | PDE5APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2434895-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2012-04-04 | — | — | EP | claimed |
| US-20120053190-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC | 2012-03-01 | — | — | US | claimed |
| US-20100323997-A1 | NOVEL USES | INTRACELLULAR THERAPIES, INC. (US) | 2010-12-23 | — | — | US | claimed |
| WO-2010132127-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-11-18 | — | — | WO | claimed |
| US-20100087450-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-04-08 | — | — | US | claimed |
| EP-2081431-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2009-07-29 | — | — | EP | claimed |
| WO-2008063505-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2008-05-29 | — | — | WO | claimed |
| EP-0538332-B1 | POLYCYCLIC GUANINE DERIVATIVES | SCHERING CORP (US) | 1997-07-23 | — | — | EP | claimed |
| WO-1991019717-A1 | POLYCYCLIC GUANINE DERIVATIVES | SCHERING CORPORATION (US) | 1991-12-26 | — | — | WO | claimed |
| US-11464781-B2 | PDE1 inhibitors for ophthalmic disorders | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| US-11166956-B2 | Combinations of PDE1 inhibitors and NEP inhibitors | INTRA-CELLULAR THERAPIES, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20190275046-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| US-10285992-B2 | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-10238660-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| WO-2008070095-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008063505-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| EP-0538332-B1 | POLYCYCLIC GUANINE DERIVATIVES | SCHERING CORP (US) | 1997-07-23 | — | — | EP | disclosed |
| US-5393755-A | Hypotensive agents, enzyme inhibitors | SCHERING CORPORATION (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0538332-A1 | POLYCYCLIC GUANINE DERIVATIVES. | SCHERING CORP (US) | 1993-04-28 | — | — | EP | disclosed |
| WO-1991019717-A1 | POLYCYCLIC GUANINE DERIVATIVES | SCHERING CORPORATION (US) | 1991-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053190-A1 | ORGANIC COMPOUNDS | PDE5A, PDE4A, PDE3A | PDE5A 1/4885PDE4A 2/4885PDE4B 8/4885 |
| US-10285992-B2 | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE4A 8/4885PDE4B 22/4885 |
| US-20100087450-A1 | ORGANIC COMPOUNDS | PDE3A, PDE5A, PDE2A | PDE5A 2/4885PDE4A 8/4885PDE4B 9/4885 |
| US-20100323997-A1 | NOVEL USES | PDE5A, PDE2A, PDE3A | PDE5A 1/4885PDE4A 4/4885PDE4B 7/4885 |
| US-10238660-B2 | Organic compounds | PDE5A, PDE4A, PDE3A | PDE5A 1/4885PDE4A 2/4885PDE4B 8/4885 |
| US-20190275046-A1 | NOVEL COMBINATION | PDE5A, PDE2A, PDE3A | PDE5A 1/4885PDE4A 9/4885PDE4B 24/4885 |
| US-11464781-B2 | PDE1 inhibitors for ophthalmic disorders | PDE12, PDE5A, PDE3A | PDE5A 2/4885PDE4A 6/4885PDE4B 12/4885 |
| US-11166956-B2 | Combinations of PDE1 inhibitors and NEP inhibitors | PDE5A, ECE1, PDE3A | PDE5A 1/4885PDE4A 10/4885PDE4B 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.